TSE:4151Pharmaceuticals
Kyowa Kirin (TSE:4151) Is Down 22.0% After Halting Rocatinlimab Trials Over Malignancy Concerns - Has The Bull Case Changed?
In early March 2026, Kyowa Kirin and Amgen discontinued all clinical trials of rocatinlimab after a planned safety review highlighted emerging malignancy concerns, including confirmed and suspected cases of Kaposi’s sarcoma potentially linked to OX40 pathway modulation.
Although overall malignancy rates reportedly remained below expected background levels, the specific pattern and biological plausibility of these cases prompted termination of the program and a full data reassessment,...